| Objective:The clinical medical records of 93 women with recurrent ovarian cancer in the department of gynecology,First Affiliated Hospital of Suzhou University were analyzed retrospectively.The effects of different clinical characteristics on the disease free interval(DFI)of ovarian cancer were analyzed.The effects of different treatments on Progression Free Survival(PFS)and Overall Survival(OS)in patients with recurrent ovarian cancer were analyzed.The aim is to provide information for predicting the risk factors of ovarian cancer recurrence,delaying the recurrence time,optimizing the treatment after recurrence,improving the prognosis of patients,and improving the survival rate of patients.Methods:A retrospective analysis was made of the clinical records of patients with recurrent ovarian cancer who received treatment in the department of gynecology,First Affiliated Hospital of Suzhou University from January 2008 to June 2018.Ovarian cancer,fallopian tube cancer and peritoneal cancer diagnosis and treatment guidelines are consistent,so this study also retrospectively analyzed the case data of fallopian tube cancer and peritoneal cancer during this period.The effects of age,neoadjuvant chemotherapy,the maximum diameter of tumor,pathological type,histological differentiation,clinical stage,residual tumor size after primary operation and the number of chemotherapy courses after primary operation on DFI were analyzed.Groups were divided according to different treatments after relapse.According to whether secondary cytoreductive surgery(SCS)was performed or not,44 cases were treated with SCS combined with chemotherapy(surgery group)and 49 cases were treated with chemotherapy alone(non-operation group).According to whether or not to use targeted drugs,they were divided into 19 cases of chemotherapy combined with targeted drugs(targeted treatment group)and 74 cases of conventional chemotherapy(non-targeted treatment group).To study the effects of two different treatment methods on PFS and OS in patients with recurrent ovarian cancer,and to analyze the survival of patients.Results:1.The single factor analysis:the degree of tissue differentiation,clinical stage,residual tumor size after the primary operation,and the number of chemotherapy courses after the primary operation were correlated with the disease-free interval(DFI)(P<0.05);age,whether neoadjuvant chemotherapy was performed,the maximum diameter of the tumor after the primary operation,and the pathological type was unrelated to the disease-free interval(DFI)(P>0.05).The higher the differentiation degree of tumor pathology,clinical staging the sooner,the smaller the primary postoperative residual tumor or tumor cells,more satisfied to destroy loss,postoperative chemotherapy regimen is sufficient specification,the disease-free survival(DFI)of patients with the longer.2.The multiple factors analysis of neoadjuvant chemotherapy,first postoperative residual tumor size associated with disease-free interval(DFI),were independent factors of ovarian cancer recurrence(P<0.05).3.The median PFS of 93 ROC patients was 12 months,and the median OS was 29 months.The median PFS was 18 months and 10 months in operation group and non-operation group respectively(x2=7.299,P<0.05),and the median OS was 32 months and 24 months 6.075,P<0.05).The median PFS and median OS in operation group were longer than those in non-operation group,and the difference was statistically significant(P<0.05).The median PFS in targeted group and non-targeted group were 12 months and 12 months respectively(x2=0.025,P>0.05),and the median OS was 26 months and 29 months(x2=0.308,P>0.05),respectively.The median PFS in targeted group was the same as that in non-targeted group,with no significant difference(P>0.05)and the median OS of the targeted group was shorter than that of the non-targeted group,also with no significant difference(P>0.05).Conclusion:1.The disease-free survival(DFI)of patients with recurrent ovarian cancer is correlated with tissue differentiation degree,clinical stage,residual tumor size after the first operation and the number of chemotherapy courses of the primary operation.2.Neoadjuvant chemotherapy and postoperative residual tumor size were independent factors for recurrence of ovarian cancer.3.The use of SCS combined with chemotherapy after ROC patients can prolong their clinical remission and improve their survival rate.Targeted drug therapy has little effect on the clinical remission and survival rate of recurrent ovarian cancer. |
PDF Full Text Request